|
Market Closed -
London S.E.
11:35:15 2026-09-01 am EDT
|
5-day change | 1st Jan Change | ||
| 1,871.50 GBX | +0.97% |
|
-1.78% | +2.58% |
| Sep. 01 | Gsk Advances Mrna Flu Vaccine Candidate to Phase Iii Following Positive Phase Ii Data | CI |
| Sep. 01 | European Stocks Close Mostly Lower in Tuesday Trading; Euro Area Inflation Surges in August | MT |
| Market Cap | 74.99B 101B 87.51B 82.32B 141B 9,628B 142B 973B 379B 4,898B 381B 373B 16,240B | P/E 2026 * |
14.1x | P/E 2027 * | 11.6x |
|---|---|---|---|---|---|
| Enterprise Value | 94.83B 128B 111B 104B 178B 12,175B 179B 1,231B 479B 6,193B 482B 471B 20,536B | EV / Sales 2026 * |
2.79x | EV / Sales 2027 * | 2.59x |
| Free-Float |
92.75% | Yield 2026 * |
3.72% | Yield 2027 * | 4.01% |
Last Transcript : GSK plc
| Sep. 01 | GSK plc : JP Morgan gives a Sell rating | ZD |
| Aug. 25 | GSK plc : Deutsche Bank remains Neutral | ZD |
| Aug. 20 | Cancer vaccines finally garner the spotlight |  |
| Aug. 19 | GSK plc : Deutsche Bank remains Neutral | ZD |
| Aug. 17 | GSK Kept at Hold as Berenberg Notes Cost Savings Plan | MT |
| 1 day | +0.97% | ||
| 1 week | -1.78% | ||
| Current month | +0.97% | ||
| 1 month | -3.11% | ||
| 3 months | +1.57% | ||
| 6 months | -14.97% | ||
| Current year | +2.58% |
| 1 week | 1,839 |  | 1,903 |
| 1 month | 1,803 | | 1,972 |
| Current year | 1,690 | | 2,282 |
| 1 year | 1,444.5 | | 2,282 |
| 3 years | 1,242.5 | | 2,282 |
| 5 years | 1,242.5 | | 3,408.16 |
| 10 years | 1,242.5 | | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | 52 | 2025-12-31 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 2023-04-30 |
James Ford
CMP | Compliance Officer | - | 2018-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | 52 | 2026-05-05 |
Hal Barron
BRD | Director/Board Member | 64 | 2017-12-31 |
Jonathan Symonds
CHM | Chairman | 67 | 2019-08-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 8/24/26 | Buy | Executive/Senior Manager | 9 | 0.0000% | ||
| 8/21/26 | Sell | Executive/Senior Manager | -28,978 | 0.0007% | ||
| 8/21/26 | Sell | Executive/Senior Manager | -49 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.97% | -1.78% | +29.29% | +34.87% | 101B | |
| +0.28% | -5.97% | +58.34% | +108.22% | 1,034B | |
| +2.01% | -0.71% | +53.07% | +68.99% | 654B | |
| +1.39% | -2.18% | +23.57% | +75.43% | 459B | |
| -1.50% | -7.04% | +33.55% | +33.94% | 343B | |
| +6.25% | +2.04% | +28.97% | +46.57% | 307B | |
| -0.07% | -4.12% | +0.95% | +11.79% | 251B | |
| +1.92% | -0.93% | +52.28% | +70.67% | 237B | |
| +0.51% | -4.52% | -19.50% | -54.83% | 202B | |
| +2.45% | +0.77% | +32.71% | +95.59% | 186B | |
| Average | +1.55% | -2.77% | +29.32% | +49.12% | 377.3B | |
| Weighted average by Cap. | +1.62% | -3.27% | +38.15% | +65.60% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.94B 45.91B 39.6B 37.25B 63.82B 4,357B 64.16B 440B 171B 2,216B 172B 169B 7,349B | 35.52B 48.05B 41.44B 38.98B 66.79B 4,560B 67.15B 461B 179B 2,319B 180B 176B 7,691B |
| Net income | 5.44B 7.35B 6.34B 5.97B 10.22B 698B 10.28B 70.54B 27.45B 355B 27.61B 27.01B 1,177B | 6.48B 8.77B 7.57B 7.12B 12.19B 833B 12.26B 84.14B 32.75B 423B 32.93B 32.22B 1,404B |
| Net Debt | 19.84B 26.84B 23.15B 21.78B 37.31B 2,547B 37.51B 257B 100B 1,296B 101B 98.58B 4,296B | 17.06B 23.08B 19.91B 18.73B 32.08B 2,190B 32.25B 221B 86.17B 1,114B 86.65B 84.77B 3,694B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-01 | GBX 1,871.50 | +0.97% | 4,720,553 |
| 26-08-28 | GBX 1,853.50 | +0.08% | 7,790,314 |
| 26-08-27 | GBX 1,852.00 | -2.50% | 3,594,876 |
| 26-08-26 | GBX 1,899.50 | -0.31% | 3,466,438 |
| 26-08-25 | GBX 1,905.50 | +0.79% | 4,599,767 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
